• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Michael Fitzhugh

Articles

ARTICLES

Heat and Oncosec seek spark in platform pairing

Feb. 19, 2015
By Michael Fitzhugh
Heat Biologics Inc. and Oncosec Medical Inc. are joining forces to evaluate the preclinical efficacy of combining Heat's tumor-specific cytotoxic T-cell immunotherapy with Oncosec's Immunopulse intratumoral DNA delivery platform in a bid to expand the impact of their technologies for the benefit of people with cancer.
Read More

VBL shares tumble on phase II misses of VB-201 in psoriasis, ulcerative colitis

Feb. 18, 2015
By Michael Fitzhugh
VBL Therapeutics shares (NASDAQ:VBLT) plummeted 65.5 percent Tuesday to $4.87, more than a dollar under the company's recent initial public offering (IPO) price, as investors digested news that VB-201, an experimental autoimmune therapy that had appeared to help patients with psoriasis in an earlier midstage study, failed to significantly benefit both psoriasis and ulcerative colitis sufferers in separate phase II trials.
Read More

Idera raising $75M to back oncology, rare disease trials

Feb. 17, 2015
By Michael Fitzhugh
About a year after its last public offering, Idera Pharmaceuticals Inc. priced a $75 million public offering Friday to advance ongoing and upcoming trials of IMO-8400, its lead Toll-like receptor antagonist candidate in development for the treatment of Waldenström's macroglobulinemia, diffuse large B-cell lymphoma (DLBCL), dermatomyositis and Duchenne muscular dystrophy (DMD).
Read More

Achillion shares rise on interim win for short-course HCV regimen

Feb. 10, 2015
By Michael Fitzhugh
Updated interim phase II data showing that a combination of Achillion Pharmaceuticals Inc.'s NS5A inhibitor, ACH-3102, and Sovaldi (sofosbuvir, Gilead Sciences Inc.) cleared hepatitis C virus (HCV) in 100 percent of 12 genotype 1 patients after just six weeks of treatment – the shortest of any two-drug, direct-acting antiviral regimen, the company said – pushed shares (NASDAQ:ACHN) up 7.8 percent to $11.66 on Monday.
Read More

Ohr raising $25M to back dual phase III studies in wet AMD

Feb. 9, 2015
By Michael Fitzhugh
Ohr Pharmaceutical Inc. is raising $25 million to fund dual pivotal phase III studies of its Lucentis-boosting eye drops, OHR-102 (squalamine), in newly diagnosed patients with AMD.
Read More

Experts taking stock of Mini-Sentinel herald its potential and challenges

Feb. 6, 2015
By Michael Fitzhugh
After nearly five years of building and testing, with the FDA's Mini-Sentinel pilot project nearing the goal of becoming the agency's next-generation safety watchdog tool, experts discussing its future in Washington said they see tremendous potential in its progress to date as well as plenty of work to be done before realizing the program's full potential.
Read More

Gilead's banner HCV sales ramp upward

Feb. 4, 2015
By Michael Fitzhugh
Sales of Gilead Sciences Inc.'s top hepatitis C virus (HCV) drugs continued to boom in the fourth quarter amid new competition, totaling about $3.8 billion, and helping lead the company to a profit more than four times higher than the same quarter last year.
Read More

Chimerix quits Ebola trials as Hemispherx gets started

Feb. 3, 2015
By Michael Fitzhugh
Chimerix Inc.'s decision Friday to cancel trials of its antiviral brincidofovir to protect against Ebola in the face of declining numbers of new infections, and thus dwindling numbers of test subjects, brought into sharp relief the hard choices small companies need to make when choosing to develop experimental treatments for neglected tropical diseases.
Read More

Spark shares double in hot IPO amid excitement for gene therapy potential

Feb. 2, 2015
By Michael Fitzhugh
Investors flocking to Spark Therapeutics Inc. more that doubled the company's value in a fiery debut that drove shares (NASDAQ:ONCE) of the gene therapy developer's upsized initial public offering (IPO) up 117.4 percent to $50 from its $23 initial offering price.
Read More

Alexion maintains Soliris momentum, changes guard with CEO retirement

Jan. 30, 2015
By Michael Fitzhugh
Rare disease specialist Alexion Pharmaceuticals Inc. is striding ahead with fast-rising sales of its sole approved product, Soliris (eculizumab), and soon a new chief executive, it said in an earnings report Thursday.
Read More
View All Articles by Michael Fitzhugh

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 8, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe